TIMM17A and neoplasm: Further subgroup analysis of multiple clinicopathological features revealed that TIMM17A mRNA expression was higher in BRCA patients than healthy individuals but did not differ according to sex, age, ethnicity, tumor stage, tumor grade, or BRCA subtype.